GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (FRA:4MNA) » Definitions » 3-Year FCF Growth Rate

Minerva Neurosciences (FRA:4MNA) 3-Year FCF Growth Rate : 29.90% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Minerva Neurosciences 3-Year FCF Growth Rate?

Minerva Neurosciences's Free Cash Flow per Share for the three months ended in Mar. 2024 was €-0.74.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 29.90% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 22.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 12 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Minerva Neurosciences was 29.90% per year. The lowest was -175.20% per year. And the median was -1.40% per year.


Competitive Comparison of Minerva Neurosciences's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Minerva Neurosciences's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minerva Neurosciences's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Minerva Neurosciences's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Minerva Neurosciences's 3-Year FCF Growth Rate falls into.



Minerva Neurosciences 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Minerva Neurosciences  (FRA:4MNA) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Minerva Neurosciences 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Minerva Neurosciences (FRA:4MNA) Business Description

Traded in Other Exchanges
Address
1500 District Avenue, Burlington, MA, USA, 01803
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences (FRA:4MNA) Headlines

No Headlines